MTRG researchers regularly publish journal articles and policy reports on issues related to medical technology policy, regulation and assessment.
Publications
-
Kamphuis, B. W. & Kanavos, P. (2021) Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration, Health Policy OPEN 2, 100045
- Angelis, A., Kanavos. P, Philips L.D. (2020) ICER Value Framework 2020 Update: recommendations on the aggregation of benefits and contextual considerations, Value in Health 23 (8), 1040-1048
- Kanavos P., Fontrier A-M., Gill J., Efthymiadou O.(2020) Does external reference pricing deliver what it promises? Evidence on its impact at national level. Eur J Health Econ 21, 129–151
- Kanavos P., Kamphuis B.W., Fontrier A-M., Colville Parkin G., Saleh S., Ahkras, K.S.(2020) Assessing External Reference Pricing (ERP) systems for in-patent pharmaceuticals in eleven MENA countries for compatibility with best practice principles for ERP, Health Policy. Volume 124, Issue 12, 1297-1309
- Miracolo A., Sophiea M., Mills M., Kanavos P. (2020) The impact of sin taxes on consumption, revenue generation and health improvement: A systematic literature review in Latin America, Health Policy and Planning, Oxford University Press
- Kanavos P., Angelis, A., Drummond M. (2019) An EU-wide approach to HTA: An irrelevant development or an opportunity not to be missed?, The European Journal of Health Economics 20 (3), 329-332
- Angelis A., Lange A., Kanavos P. (2018) Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries, The European Journal of Health Economics 19 (1),123-152
- Efthymiadou O., Mossman J, Kanavos P. (2018) Health Related Quality of Life aspects not captured by EQ- 5D-5L: Results from an international survey of patients, Health Policy. 2018 Dec 14
- Efthymiadou O, Kanavos P, Mossman J. (2018) Differentiation of Health-Related Quality of Life outcomes between five disease areas; results from an international survey of patients, Int J Technol Assess Health Care. 2018 Jan; 34(5), 498-506
- Tinelli M, Kanavos P, Efthymiadou O, Visintin E, Grimaccia F, Mossman J. (2018) Using IMPrESS to guide policy change in multiple sclerosis, Mult Scler. 2018 Aug; 24(9), 1251-1255
- Angelis A., Montibeller G., Hochhauser D., Kanavos P. (2017) Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting, BMC Medical Informatics and Decision Making 17 (1), 149
- Angelis A., Tordrup D., Kanavos P. (2017) Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries, Global Policy 8, 7-22
Policy reports
- Kamphuis B.W., Efthymiadou, O., Tzouma, V. & Kanavos, P. (2021) Severe asthma care and treatment: Indicators and data for performance management across ten countries, The London School of Economics and Political Science, London, UK.
- Efthymiadou, O., Kamphuis B.W., Tzouma, V. & Kanavos, P. (2021) Treatment gaps in severe asthma across nine OECD countries and recommendations for addressing them: An international survey of clinicians, The London School of Economics and Political Science, London, UK.
- (2021) MSD Global Oncology Policy 2019 Grants Program: Report of the Inaugural Forum, The London School of Economics and Political Science, London, UK.
- Gill JL., Fontrier A-M., Miracolo A. & Kanavos P. (2020) Access to Personalised Oncology in Europe, The London School of Economics and Political Science, London, UK.
- Kanavos P., Colville Parkin G., Kamphuis B.W. & Gill J. (2019) Latin America Healthcare System Overview: A comparative analysis of fiscal space in healthcare, The London School of Economics and Political Science, London, UK.
- Gill J. et al. (2018) Paper IV: Engaging Pharma in the RWE Roadmap, The London School of Economics and Political Science, London, UK.
- Kamphuis B.W. et al. (2018) Paper V: Policy Challenges around Real World Evidence Adoption in Europe, The London School of Economics and Political Science, London, UK.
- Kanavos P., Tzouma V., Fontrier A-M., Kamphuis B.W., Colville Parkin G., Saleh S. (2018) Pharmaceutical Pricing and Reimbursement in the Middle East and North Africa Region: A Mapping of the Current Landscape and Options for the Future, The London School of Economics and Political Science, London, UK.
- Kanavos P, Tzouma V, Efthymiadou O, Mills M, Flannelly C. (2018) Accelerated Approval and Access Schemes: A mapping of policies across the globe and the impact of accelerated approval on the HTA of new oncology medicines, The London School of Economics and Political Science, London, UK.
- Gill J. et al. (2017) Paper II: The Use of Real World Evidence in the Disease Context, The London School of Economics and Political Science, London, UK.
- Gill J. et al. (2017) Paper III: A Roadmap for RWE, The London School of Economics and Political Science, London, UK.
- Kanavos P, Fontrier A-M, Gill J, Efthymiadou O, Boekstein N (2017), The Impact of External Reference Pricing within and across Countries, London School of Economics, London, UK
- Gill J. et al. (2016) Paper I: The Use of Real World Evidence in the European Context, The London School of Economics and Political Science, London, UK.
- Kanavos P, Tinelli M, Efthymiadou O, Visintin E, Grimaccia F, Mossman J (2016) Towards better outcomes in multiple sclerosis by addressing policy change: the International MultiPlE Sclerosis Study (IMPrESS), The London School of Economics and Political Science, London, UK.
- Tinelli M., Kanavos P. (2015) Cost and Impact of Non-Treating Severe Mental Illnesses (SMIs): The Case Study of Schizophrenia, The London School of Economics and Political Science, London, UK.